RMD241018C220000
- 22.70
- -2.70-10.63%
ResMed Newsroom
Baird Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $280
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $270
Resmed Poised for Growth Amid Rising OSA Diagnosis and Market Opportunity: Buy Rating Reaffirmed With Increased Price Objective
ResMed (NYSE:RMD) Eyes Growth With Board Expansion and Solid Earnings Despite Freight Cost Challenges
Baird Starts ResMed at Outperform, Cites Growing Sleep Apnea Market
Baird Initiates Coverage On ResMed With Outperform Rating, Announces Price Target of $280
ResMed Analyst Ratings
Baird Initiates ResMed(RMD.US) With Buy Rating, Announces Target Price $280
Baird analyst David Rescott initiates coverage on $ResMed(RMD.US)$ with a buy rating, and sets the target price at $280.According to TipRanks data, the analyst has a success rate of 46.8% and a
ResMed Inc. (NYSE:RMD) Is a Favorite Amongst Institutional Investors Who Own 74%
ResMed (NYSE:RMD) Shareholders Have Earned a 14% CAGR Over the Last Five Years
Is ResMed Stock Outperforming the S&P 500?
US stocks mining | The Federal Reserve cuts interest rates more than expected! Multiple real estate-related stocks reach new highs for the year; Accelerate the acquisition plan, US private equity giant KKR rises more than 9% in five days
Soft landing expected to ignite! ai optical communication company Coherent rose nearly 4% on the previous trading day, with a cumulative increase of nearly 90% within the year; ai cloud computing service platform servicenow hit another historical high intraday, with a total annual increase of over 26%.
Why ResMed Stock Tumbled by 5% Today
Equity Markets Fall After 50-Basis-Point Fed Rate Cut
US Equities Markets End Lower Wednesday After FOMC Cuts Rates
ResMed Slips as Wolfe Downgrades on GLP-1 Threat From Lilly
These Are the Mid-caps That Could Perform Best During 'Downturn' Regimes – BofA
Equity Markets Eke Out Gains Ahead of Fed Decision
Sector Update: Health Care Stocks Advance in Afternoon Trading